Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Appian Corp (APPN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Appian Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Appian Corp trades at $24.36 (market cap $1.81B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.5× Appian Corp's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Appian Corp nearer its low. Which is the better fit depends on your goals.
| ACAD | APPN | |
|---|---|---|
Market Cap | $4.49B | $1.81B |
Sector | Health | Technology |
52-Week High | $28.06 | $45.64 |
52-Week Low | $20.06 | $18.72 |
Enterprise Value | $3.69B | $1.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Appian (APPN) trades at $24.68, up 1.15% with bullish technical signals from moving averages. The company shows strong revenue growth reaching $727M in 2025 and has beaten earnings estimates for three consecutive quarters. However, profitability remains minimal with a net margin of just 0.12% and negative shareholder equity of -$32.64M. Recent CEO stock sales and mixed analyst sentiment create uncertainty despite positive AI-driven business developments.
Appian presents a growth story with improving cash flow and AI positioning, but faces significant profitability challenges and negative equity. The stock trades near analyst consensus target of $26.20, suggesting limited upside. Key risks include sustained unprofitability and high debt levels, while opportunities lie in enterprise AI adoption and cloud revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Appian Corp
Appian Corp provides a low-code software development platform as a service that enables organizations to rapidly develop powerful and unique applications. With its platform, organizations can rapidly and easily design, build and implement powerful, enterprise-grade custom applications through intuitive, visual interface with little or no coding required. The company's customers use applications built on its low-code platform to launch new business lines, automate vital employee workflows, manage complex trading platforms, accelerate drug development and build procurement systems. The group generates a majority of its revenue from the domestic market. It serves various industries such as education.
Read more on APPN →
